NCT03119519

Local Non-salvage Radiotherapy for Synchronous Oligometastatic Non-small-cell Lung Cancer.

Local Non-salvage Radiotherapy for Synchronous Oligometastatic Non-small-cell Lung Cancer :A Multicenter,Randomized,Controlled,Phase 2 Study.

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 148 (estimated)
• Sponsor: Southern Medical University, China · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Aggressive therapy may improve survival in synchronous oligometastatic NSCLC and the goal of this clinical trial is to assess the efficacy and safety of local definitive radiotherapy in this subset of patients.

Detailed description

For NSCLC patients with synchronous oligometastases, first line chemotherapy or targeted therapy concurrent with non-salvage radiotherapy on metastatic or primary thoracic tumor contributed a longer progression-free survival than chemotherapy or targeted therapy alone.

Conditions

• Stage IV Non-small Cell Lung Cancer

Interventions

Type	Name	Description
RADIATION	Local Definitive Radiotherapy	three-dimensional conformal therapy or intensity modulated radiation therapy
DRUG	No Local Definitive Radiotherapy	Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) alone, according to gene test.

Timeline

• Start date: 2017-12-11
• Primary completion: 2020-09-01
• Completion: 2021-09-01
• First posted: 2017-04-18
• Last updated: 2020-03-18

Locations

1 site across 1 country: China